Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Pancreatic Cancer Early Detection
Pancreatic Cancer Early Detection

Pancreatic Cancer Early Detection

Clinicaltrials.gov identifier:
NCT02206360

Prevention

Study Contact Information:

Lisa Schuldt, BSN 
914-849-7582
lschuldt@wphospital.org

 

 


Pancreatic Cancer Early Detection Program

About the Study

This is a study looking at esophageal as a screening for pancreatic cancer in high risk individuals. The study will enroll people with an inherited risk for cancer due to a or CDKN2A mutation with or without a family history of pancreatic cancer. The study will also enroll people with a first- or second-degree relative with pancreatic cancer with (, , , , ) or any of the following mutations P53, , APC, or . 

What the Study Entails

Enrolled subjects will undergo Endoscopic (EUS) alternating with Magnetic Resonance Imaging (), every six to 12 months, for up to 5 years.

Study Site

White Plains, NY
White Plains Hospital
Lisa Schuldt, BSN by phone: 914-849-7582 or email lschuldt@wphospital.org

Study Lead Investigator

Principal Investigator: Joshua P Raff, MD    

This Study is Open To:

People at elevated risk for pancreatic cancer

  • Known carrier of either the or CDKN2A mutation
  • Known carrier of any of the following mutations (, , , , , , P53, , APC, or ) PLUS first- or second-degree relative affected with pancreatic cancer;
  • Individual with Peutz-Jeghers Syndrome;
  • Familial Pancreatic Cancer, defined as at least two affected relatives with Pancreatic Cancer, who are with each other, and at least one of those affected must be first degree relative to the study subject;
  • Both parents affected, any age:
  • Any first degree relative diagnosed with pancreatic cancer under age 50;
  • Chronic Pancreatitis Syndrome, defined by either PRSS1 or SPINK1 mutations AND appropriate clinical and family history
This Study is Not Open To:

Patients are excluded if they have:

  • any medical condition that contraindicates endoscopy or biopsy
  • any medical condition that contraindicates
  • history of pancreatic cancer, either endocrine or exocrine
  • clinical suspicion of pancreatic cancer, or any previous radiographic or histologic diagnosis of a pre-malignant finding, including IPMN (Intraductal papillary mucinous neoplasm) and PanIN (Pancreatic intraepithelial Neoplasm).
  • diagnosis of dementia
  • uncontrolled, current illness
  • renal insufficiency with serum creatinine greater than 2.0 mg/dl